All questionsSafety: Stelara (ustekinumab), all indications8 questions · 3 sourcesWarningsDoes Stelara raise the risk of mycobacterial or Salmonella infections?“Individuals genetically deficient in IL-12/IL-23 are particularly vulnerable to disseminated infections from mycobacteria (including nontuberculous, environmental mycobacteria), salmonella (including nontyphi strains), and Bacillus Calmette-Guerin (BCG) vaccinations. Serious infections and fatal outcomes have been reported in such patients. It is not known whether patients with pharmacologic blockade of IL-12/IL-23 from treatment with STELARA may be susceptible to these types of infections. Consider appropriate diagnostic testing, (e.g., tissue culture, stool culture, as dictated by clinical circumstances).” (opens the source at this quote in a new tab)CopyFlagWhat are the contraindications for Stelara?“STELARA is contraindicated in patients with clinically significant hypersensitivity to any ustekinumab product or to any of the excipients in STELARA [see Warnings and Precautions (5.5)].” (opens the source at this quote in a new tab)CopyFlagCan Stelara cause serious allergic reactions?“Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with STELARA in clinical trials and postmarketing. Some serious hypersensitivity reactions have occurred during the first intravenous dose of STELARA [see Adverse Reactions (6.1, 6.2)]. If a severe or clinically significant hypersensitivity reaction occurs, discontinue STELARA immediately and initiate appropriate medical treatment [see Contraindications (4)].” (opens the source at this quote in a new tab)CopyFlag“Immune system disorders: Hypersensitivity reactions (e.g., anaphylaxis, angioedema, dyspnea, rash, urticaria), including a fatal case that presented with chest tightness and dyspnea during infusion of the first dose. Some cases of serious hypersensitivity reactions have been reported in patients with a history of alpha- gal syndrome, allergy to mammalian meat or meat products, or anti-alpha-gal IgE. In most of these cases the reactions occurred at the time of initial administration.” (opens the source at this quote in a new tab)CopyFlagNote: Stelara is given intravenously only as the induction dose for Crohn's disease and ulcerative colitis; plaque psoriasis dosing is subcutaneous.Can Stelara cause PRES (posterior reversible encephalopathy syndrome)?“Two cases of posterior reversible encephalopathy syndrome (PRES), also known as Reversible Posterior Leukoencephalopathy Syndrome (RPLS), were reported in clinical trials. Cases have also been reported in postmarketing experience in patients with psoriasis, psoriatic arthritis, and Crohn’s disease. Clinical presentation included headaches, seizures, confusion, visual disturbances, and imaging changes consistent with PRES a few days to several months after ustekinumab initiation. A few cases reported latency of a year or longer. Patients recovered with supportive care following withdrawal of ustekinumab. Monitor all patients treated with STELARA for signs and symptoms of PRES. If PRES is suspected, promptly administer appropriate treatment and discontinue STELARA.” (opens the source at this quote in a new tab)CopyFlag“One Case of Posterior Reversible Encephalopathy Syndrome (PRES) occurred during adult plaque psoriasis clinical studies.” (opens the source at this quote in a new tab)CopyFlagCan Stelara cause noninfectious pneumonia?“Cases of interstitial pneumonia, eosinophilic pneumonia, and cryptogenic organizing pneumonia have been reported during post-approval use of STELARA. Clinical presentations included cough, dyspnea, and interstitial infiltrates following one to three doses. Serious outcomes have included respiratory failure and prolonged hospitalization. Patients improved with discontinuation of therapy and in certain cases administration of corticosteroids. If diagnosis is confirmed, discontinue STELARA and institute appropriate treatment [see Adverse Reactions (6.2)].” (opens the source at this quote in a new tab)CopyFlagSide effectsCan Stelara cause pustular or erythrodermic psoriasis?“The following adverse reactions have been reported during post-approval use of STELARA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to STELARA exposure.” (opens the source at this quote in a new tab)CopyFlag“Skin reactions: Pustular psoriasis, erythrodermic psoriasis, hypersensitivity vasculitis.” (opens the source at this quote in a new tab)CopyFlagVaccinesCan patients on Stelara get live vaccines?“Prior to initiating therapy with STELARA, patients should receive all age- appropriate immunizations as recommended by current immunization guidelines. Patients being treated with STELARA should avoid receiving live vaccines. Avoid administering BCG vaccines during treatment with STELARA or for one year prior to initiating treatment or one year following discontinuation of treatment. Caution is advised when administering live vaccines to household contacts of patients receiving STELARA because of the potential risk for shedding from the household contact and transmission to patient. Non-live vaccinations received during a course of STELARA may not elicit an immune response sufficient to prevent disease.” (opens the source at this quote in a new tab)CopyFlagSafetyHow do I report a Stelara side effect?“To report SUSPECTED ADVERSE REACTIONS, contact Janssen Biotech, Inc. at 1-800-526-7736 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.” (opens the source at this quote in a new tab)CopyFlag“You can also report a side effect or product complaint of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.” (opens the source at this quote in a new tab)CopyFlag